Has Acumen Pharmaceuticals (ABOS) Outpaced Other Medical Stocks This Year?

Group 1 - Acumen Pharmaceuticals, Inc. (ABOS) has gained approximately 8.6% year-to-date, outperforming the Medical sector average return of 7.1% [2][3] - The Zacks Rank for Acumen Pharmaceuticals is currently 2 (Buy), indicating a favorable outlook based on earnings estimate revisions [2] - The Zacks Consensus Estimate for ABOS' full-year earnings has increased by 3.2% over the past three months, reflecting improving analyst sentiment [2] Group 2 - Acumen Pharmaceuticals belongs to the Medical - Biomedical and Genetics industry, which consists of 515 companies and currently ranks 87 in the Zacks Industry Rank [3] - The Medical - Biomedical and Genetics industry has seen an average gain of 3% year-to-date, with ABOS outperforming this average [3] - Akoya Biosciences (AKYA) is another stock in the Medical sector that has performed well, returning 16% since the beginning of the year [2][3]